apollomicsinc.com (APLM): Debts to Book Capitalization

Graphic logo of Apollomics (APLM)

Apollomics, Inc. (APLM) volatility is driven by BioSecure Act risks and dependence on China. The debt-to-balance sheet capitalization ratio visualizes these fluctuations, where 0.00 reflects the metric's latest value. Stability will require overcoming biomed sanctions and optimizing laboratory costs to avoid linear expense growth as the drug portfolio expands.

Apollomics Inc. (APLM) - Debts to Book Value from 02/21/2024 to 10/27/2026
Core merchandise of apollomicsinc.com

This indicator determines the ratio of borrowed funds to total equity. By analyzing the debt-to-capitalization financial stability metric, an investor assesses the extent to which the financing structure depends on creditors. The metric measures insolvency risk by comparing liabilities against the book value of assets. For Apollomics, Inc. (APLM), a low debt level is critical, as it ensures developmental autonomy for oncology therapy clinical trials regardless of external market conditions.

Who Apollomics, Inc. competes with

ONC - Debt to Book Capitalization Ratio|Debt to Book Value Ratio halozyme.com HALO|RVMD: Debts to Book Capitalization|AAPG - Debt to Book Value|Debts to Book Capitalization CGON|URGN (UroGen Pharma Corp) - Debts to Book Value|BCAX - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio personalis.com (PSNL)|Erasca (ERAS) - Debt to Book Value|Debt to Net Assets Ratio Delcath Systems Inc (DCTH)|YmAbs - Debts to Book Capitalization|AURA - Debt to Book Value|Candel - Debt to Book Value|ARAY: Debts to Book Capitalization|Debt to Book Capitalization Ratio sellaslifesciences.com SLS|Actuate Therapeutics Inc. (ACTU) - Debt to Net Assets Ratio|Debts to Book Capitalization CTOR (Citius Oncology, Inc)|Debts to Book Value TuHURA|Debts to Book Capitalization TARA|Debts to Book Capitalization FATE (fatetherapeutics.com)|Aadi Bioscience (WHWK) - Debt to Book Capitalization Ratio|TScan Therapeutics Inc - Debts to Book Capitalization Ratio|CSBR (Champions Oncology Corp) - Debt to Book Capitalization Ratio|XBIT: Debts to Book Value|cel-sci.com (CVM) - Debt to Book Capitalization Ratio|OSTX (ostherapies.com) - Debt to Book Capitalization Ratio|Debt to Book Capitalization Ratio Radiopharm Theranostics Limited|Debt to Book Capitalization Ratio ARTV|Adlai Nortye Ltd. - Debt to Book Capitalization Ratio|Debts to Book Value VERU (Veru Corporation)|Tempest Therapeutics - Debt to Book Capitalization Ratio|Debt to Book Value Xilio Therapeutics Inc XLO|Debts to Book Capitalization RENB (Enochian BioSciences)|MURA - Debts to Net Assets|KAPA (kairospharma.com) - Debts to Book Capitalization|OKUR (OnKure Therapeutics) - Debt to Book Value|GDTC: Debt to Book Capitalization Ratio|Debts to Net Assets Curis Corp (CRIS)|Tharimmune (THAR) - Debt to Book Value|Debt to Net Assets Ratio advanbiomed.com (ADVB)|Debts to Book Capitalization GNPX|Calidi Biotherapeutics Inc. - Debts to Net Assets|Sunshine Biopharma, Inc. (SBFM) - Debt to Book Capitalization Ratio|XBIO - Debt to Book Value Ratio|SLRX (Salarius Pharmaceuticals, Inc.) - Debts to Book Capitalization|Debt to Book Value Purple Biotech Ltd|AONC: Debt to Book Value|Debts to Net Assets BeiGene Ltd|Debts to Book Capitalization CKPT|Debts to Book Capitalization ELEV (elevationoncology.com)|iCAD (ICAD) - Debt to Book Capitalization Ratio|Ikena Oncology Inc. - Debts to Book Capitalization Ratio|NTBL - Debt to Book Capitalization Ratio|VIRX: Debt to Book Capitalization Ratio|MOR (MorphoSys AG) - Debt to Book Capitalization Ratio|nayabiosciences.com (NAYA) - Debt to Book Value|Debts to Book Capitalization AAPGV